Skip to main
TDOC

Teladoc (TDOC) Stock Forecast & Price Target

Teladoc (TDOC) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 14%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Teladoc Health is in a precarious position as they navigate a transition from a stable, subscription-based business model to a more volatile, visit-based one, causing uncertainty and a deceleration in revenue growth. However, their ability to deliver whole-person care through their virtual platform gives them a unique advantage and potential for long-term growth. Their success will depend on continued expansion into virtual care and the ability to stabilize revenue and improve profitability.

Bears say

Teladoc Health is facing multiple challenges, including a reliance on their Integrated Care segment for the majority of their revenues, which may be negatively impacted by expected membership declines due to changes in health plan customer enrollment and the expiration of ACA subsidies. The transition to a broader commercial model for their BetterHelp segment could also lead to uncertainty and potential margin pressures. Additionally, the company's focus on AI investments and their lack of pricing power may limit their ability to drive long-term growth and profitability. These factors, combined with potential competitive pressures and the need for significant sales and marketing spend, lead to a negative outlook on Teladoc Health's stock.

Teladoc (TDOC) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teladoc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teladoc (TDOC) Forecast

Analysts have given Teladoc (TDOC) a Buy based on their latest research and market trends.

According to 14 analysts, Teladoc (TDOC) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teladoc (TDOC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.